Results 281 to 290 of about 349,122 (350)

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

open access: yesRheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen   +6 more
wiley   +1 more source

Farnesoid X receptor prevents hyperuricemia via activating ATP‐binding cassette subfamily G member 2

open access: yesRheumatology &Autoimmunity, EarlyView.
Farnesoid X receptor (FXR) activation reduces serum uric acid levels by upregulating the intestinal urate transporter ATP‐binding cassette subfamily G member 2 (ABCG2). These findings uncover a novel metabolic pathway for urate excretion and suggest that FXR agonists (e.g., obeticholic acid), represent a promising therapeutic strategy for the treatment
Rui Li   +5 more
wiley   +1 more source

Cardiac disease in systemic sclerosis: Integrating pathobiology with clinical management

open access: yesRheumatology &Autoimmunity, EarlyView.
Abstract Systemic sclerosis (SSc) is a complex autoimmune disorder in which cardiovascular involvement remains a major determinant of morbidity and mortality. Cardiac injury in SSc results from the interplay of microvascular dysfunction, immune‐mediated inflammation, and progressive interstitial and replacement fibrosis, leading to myocardial disease ...
Henry Sutanto, Betty Rachma, Yuliasih
wiley   +1 more source

Obstructive sleep apnea and cardiovascular disease in individuals with metabolic dysfunction‐associated fatty liver disease: A prospective cohort study

open access: yesSleep Research, EarlyView.
Abstract Objective To assess the association between obstructive sleep apnea (OSA) risk levels and major cardiovascular disease (CVD) subtypes in individuals with metabolic dysfunction‐associated fatty liver disease (MAFLD). Methods This cohort study included 128,022 MAFLD participants from the UK Biobank without CVD at baseline.
Haizhen Chen   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy